Ginkgo Bioworks Holdings Inc vs Solaredge Technologies Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Solaredge Technologies Inc trades at $56.02 (market cap $3.38B). The key difference: Solaredge Technologies Inc is far larger — about 5.7× Ginkgo Bioworks Holdings Inc's market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | SEDG | |
|---|---|---|
Market Cap | $590.53M | $3.38B |
Sector | Health | Technology |
52-Week High | $16.14 | $78.51 |
52-Week Low | $5.48 | $24.42 |
Enterprise Value | $627.78M | $3.31B |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
SolarEdge Technologies (SEDG) trades at $52.13, down 5.53% amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -28.56% net margin and -72.5% ROE, though recent quarters saw earnings beats. Revenue declined from $3.1B in 2022 to $1.18B in 2025, reflecting solar market challenges. Analyst sentiment is cautious with a $35.56 consensus target below current price, while technical indicators show bearish momentum with key support at $49.
SEDG faces significant headwinds with persistent losses and declining revenue, though operational cash flow turned positive in 2025. Investment opportunity exists if solar demand recovers, but risks include intense competition, policy uncertainty, and high debt levels. The stock remains speculative with substantial downside risk to analyst targets.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →